GLP-1 weight loss results.
What to realistically expect from GLP-1 medicines: the trial numbers for Mounjaro, Wegovy, the Wegovy pill and Foundayo, minus the hype.
Marketing loves a big number. Here's what the clinical trials actually measured — average body-weight loss at the highest dose, over roughly 72 weeks, alongside diet and activity changes:
- Mounjaro (tirzepatide) — around 20–22.5% average at the highest doses, the class leader
- Wegovy injection (semaglutide 2.4mg) — around 15%; up to roughly 20% at the 7.2mg dose
- Wegovy pill (oral semaglutide) — around 13.6–14%
- Foundayo (orforglipron) — 11.2% at the highest dose in ATTAIN-1
Reading those numbers honestly
They're averages — individual results spread widely in both directions. They assume consistent use over more than a year. And weight typically returns if the medicine stops without other changes in place, which is why Foundayo's licence covering weight maintenance after injections matters.
Higher efficacy usually means a higher price, but the right medicine is the one a prescriber matches to your health — then you find its best price: Monj · iGovy · oGovy · Frayo.
Live prices, per medication.
The official sources, in one place.
These are the bodies that actually regulate, appraise and advise. If anything you read anywhere — including here — disagrees with them, believe them.